Your browser doesn't support javascript.
loading
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau, Thomas; Park, Joong-Won; Finn, Richard S; Cheng, Ann-Lii; Mathurin, Philippe; Edeline, Julien; Kudo, Masatoshi; Harding, James J; Merle, Philippe; Rosmorduc, Olivier; Wyrwicz, Lucjan; Schott, Eckart; Choo, Su Pin; Kelley, Robin Kate; Sieghart, Wolfgang; Assenat, Eric; Zaucha, Renata; Furuse, Junji; Abou-Alfa, Ghassan K; El-Khoueiry, Anthony B; Melero, Ignacio; Begic, Damir; Chen, Gong; Neely, Jaclyn; Wisniewski, Tami; Tschaika, Marina; Sangro, Bruno.
Afiliación
  • Yau T; Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China. Electronic address: the@netvigator.com.
  • Park JW; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, South Korea.
  • Finn RS; Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Cheng AL; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.
  • Mathurin P; Centre Hospitalo-Universitaire Claude Huriez, Service d'Hépatologie, Lille, France.
  • Edeline J; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Kudo M; Kindai University Faculty of Medicine, Osaka, Japan.
  • Harding JJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical Center, New York, NY, USA.
  • Merle P; Hepatology Unit, Croix-Rousse Hospital, Lyon, France.
  • Rosmorduc O; Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière-Université Pierre et Marie Curie, Paris, France.
  • Wyrwicz L; M Sklodowska-Curie Memorial National Cancer Research Institute, Warsaw, Poland.
  • Schott E; Helios Klinikum Emil von Behring GmbH, Klinik für Innere Medizin II, Berlin, Germany.
  • Choo SP; National Cancer Centre Singapore, Singapore.
  • Kelley RK; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Sieghart W; Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Liver Cancer (HCC) Study Group, Medical University Vienna, Vienna, Austria.
  • Assenat E; Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi Medical Oncology, Montpellier, France.
  • Zaucha R; Department of Clinical Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
  • Furuse J; Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical Center, New York, NY, USA.
  • El-Khoueiry AB; University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Melero I; Department of Immunology and Immunotherapy, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain.
  • Begic D; Bristol Myers Squibb, Princeton, NJ, USA.
  • Chen G; Bristol Myers Squibb, Princeton, NJ, USA.
  • Neely J; Bristol Myers Squibb, Princeton, NJ, USA.
  • Wisniewski T; Bristol Myers Squibb, Princeton, NJ, USA.
  • Tschaika M; Bristol Myers Squibb, Princeton, NJ, USA.
  • Sangro B; Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain.
Lancet Oncol ; 23(1): 77-90, 2022 01.
Article en En | MEDLINE | ID: mdl-34914889
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Sorafenib / Nivolumab / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Guideline Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Sorafenib / Nivolumab / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Guideline Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article